X4 Pharmaceuticals’ (XFOR) Overweight Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $3.00 target price on the stock. Separately, HC Wainwright reiterated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a […]
Cantor Fitzgerald reiterated their overweight rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $3.00 target price on the stock. Separately, HC Wainwright reiterated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a […]
